Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — 15th International Conference on Malignant Lymphoma (ICML) 2019
11 slides from Innate Pharma Sa Class A's conference presentation, 2019
Slide 1: TELLOMAK: T-Cell Lymphoma Anti-KIR3DL2 Therapy
TELLOMAK: T-CELL LYMPHOMA ANTI-KIR3DL2 THERAPY An open label, multi-cohort, multi-center, international phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma Pierluigi Porcu 1, Youn H. Kim 2 , Pier Luigi Zinza
Slide 2: Conflict of Interest Disclosure – Pierluigi Porcu
Conflict of Interest Disclosure – Pierluigi Porcu - Employment or leadership position: N/A - Consultant or advisory role: Innate Pharma - Stock ownership: N/A - Honoraria: N/A - Research funding: Kyowa Kirin, Viracta - Other remuneration: N/A
Slide 3: IPH4102: First in Class mAb Directed Against KIR3DL2
IPH4102 FIRST IN CLASS mAb DIRECTED AGAINST KIR3DL2 NK cells kill primary Sézary cells in ex vivo autologous model through IPH4102-mediated ADCC (2 representative SS patients) VL IPH4102 KIR3DL2 100 100 D0 % dead tumor cells 80 80 IPH4102 rituximab 60 60 alemtuzumab D1 40 40 20 20 VH 0 0 D2 E/T rati
Slide 4: KIR3DL2 Is Expressed in Cutaneous T Cell Lymphoma
KIR3DL2 IS EXPRESSED IN CUTANEOUS T CELL LYMPHOMA % of samples with at least 5% of cells expressing KIR3DL2 Mycosis ~50% fungoides Sézary ~85% Syndrome KIR3DL2 expression in KIR3DL2 expression in Sézary Mycosis Fungoides syndrome Battistella M et al, Blood 2017 Porcu P, 15-ICML 2019 Page 4
Slide 5: Results of First-in-Human Phase 1 Study
RESULTS OF FIRST-IN-HUMAN PHASE 1 STUDY GOOD SAFETY PROFILE AND HIGH ACTIVITY OF IPH4102 IN SÉZARY SYNDROME • Phase 1: N=44 Advanced CTCL, 80% (n=35) were Sézary Syndrome • ≥ 2 prior systemic therapies, 39% ≥ 5th line of Global response: 42.9% (95%CI: 28 – 59) therapy Median DOR: 13.8m (95%CI: 7.2 –
Slide 6: IPH4102 in Peripheral T-Cell Lymphoma Rationale
IPH4102 IN PERIPHERAL T-CELL LYMPHOMA RATIONALE Expression of KIR3DL2 In vitro combination of IPH4102 with in PTCL subtypes gemcitabine / oxaliplatin (GEMOX) AITL Enhanced (9/25, 36%) ADCC of IPH4102 by GEMOX PTCL-NOS (7/20, 35%) Increased surface KIR3DL2 ALCL expression by GEMOX (8/14, 57%) AITL: A
Slide 7: TELLOMAK: A Multi-cohort International Phase 2 Trial
TELLOMAK : T-CELL LYMPHOMA ANTI-KIR3DL2 THERAPY A Multi-cohort International Phase 2 Trial N~60 Sézary Syndrome Cohort # 1 ≥ 2 prior systemic therapies that must include mogamulizumab IPH4102 N~90 Mycosis Fungoides single agent ≥ 2 prior systemic therapies including biological agents Cohort # 2 KIR3
Slide 8: Key Eligibility Criteria
KEY ELIGIBILITY CRITERIA Sézary Syndrome Mycosis Fungoides Peripheral T Cell Lymphoma • Relapsed/refractory SS • Relapsed refractory MF • Relapsed PTCL (ALCL, AITL, PTCL-NOS subtypes) • ≥ 2 prior systemic therapies, must include • ≥ 2 prior systemic therapies; • ≥ 1 prior systemic therapies; mogamul
Slide 9: Schedule of Administration & Disease Evaluation
SCHEDULE OF ADMINISTRATION & DISEASE EVALUATION Cohorts 1-3 (SS & MF) Single agent IPH4102 750mg (30 minute IV infusion) • weekly x 4, every 2 weeks x 10, every 4 weeks until progression or unacceptable toxicity. • Disease evaluation after 1 month and then every 2 months x 1 year followed by every 3
Slide 10: Study Endpoints
STUDY ENDPOINTS • Primary endpoint > Overall response rate • Cohort 1-3 (International consensus criteria, Olsen 2011) • Cohort 4-5 (Lugano criteria, Cheson 2014) • Key secondary endpoints > Toxicity; > Duration of response, PFS, OS at 1 and 2 years; > Quality of life (QoL); > PK and immunogenicity
Slide 11: Key Facts
KEY FACTS • Open in US, France, Italy, UK, Germany and Spain with target activation of around 40 centers. • Target recruitment ~ 250 patients, with Simon 2-stage biomarker-stratified design in cohorts 2-5 to allow early stopping for futility. • Governed by IDMC to ensure patient safety and study pro
Innate Pharma — 15th International Conference on Malignant Lymphoma (ICML) 2019 on 6ix